ImmunoGen CEO and leadership

Mr. Enyedy joined ImmunoGen as President and Chief Executive Officer in 2016, bringing over twenty-five years of combined general management, business development, and legal experience in the biotechnology industry. Prior to ImmunoGen, he served as Executive Vice President and Head of Corporate Development for Shire plc leading the company’s Strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the Board of Directors of Akebia Therapeutics, Inc. and The American Cancer Society of Eastern New England. He previously served on the Board of Directors of Fate Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc.

ANNA BERKENBLIT is a Senior Vice President, Chief Medical Officer at IMMUNOGEN INC.

Seasoned biotech professional with over 20 years of experience at pioneering organizations including Genzyme, Sanofi, Editas, and ImmunoGen. Have led all aspects of business development in multiple therapeutic areas such as oncology, transplant, multiple sclerosis, and rare diseases.

Susan Altschuller is a Chief Financial Officer at IMMUNOGEN INC and is based in Boston, Massachusetts. She has worked as Executive Director, Investor Relations at BIOVERATIV INC.; Associate Director, Investor Relations at BIOGEN INC.; and Senior Consultant at Frankel Group. Susan works or has worked as Exec Dir:Investor Relations at BIOVERATIV INC.. She attended Illinois Institute of Technology between 2003 and 2007, Tulane University between 1999 and 2003, and MIT between 2007 and 2009.

Audrey Bergan is a VP/Chief Human Resources Ofcr at IMMUNOGEN INC and is based in Greater Boston Area. She has worked as Director, Talent Acquisition R & D and Corporate Functions at BIOGEN INC.; Director, Talent Acquisition - Executive Services Americas at Philips; and Staffing Consultant at Pfizer. AUDREY works or has worked as Exec Dir:HR at IMMUNOGEN INC. She attended University of Massachusetts - Amherst - UMASS between 1986 and 1990 and Northeastern University between 1991 and 1993.

Mr. Enyedy joined ImmunoGen as President and Chief Executive Officer in 2016, bringing over twenty-five years of combined general management, business development, and legal experience in the biotechnology industry. Prior to ImmunoGen, he served as Executive Vice President and Head of Corporate Development for Shire plc leading the company’s Strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the Board of Directors of Akebia Therapeutics, Inc. and The American Cancer Society of Eastern New England. He previously served on the Board of Directors of Fate Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc.